Journal articles on the topic 'P-tau181'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'P-tau181.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Xia, Chenyu, and Qiang Ma. "The Levels of Amyloid β-Protein and P181 in Peripheral Blood of Patients with Alzheimer’s Disease Combined with Helicobacter pylori Infection and Their Clinical Significance." Computational and Mathematical Methods in Medicine 2021 (December 20, 2021): 1–6. http://dx.doi.org/10.1155/2021/7135399.
Full textBenussi, Alberto, Thomas K. Karikari, Nicholas Ashton, Stefano Gazzina, Enrico Premi, Luisa Benussi, Roberta Ghidoni, et al. "Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration." Journal of Neurology, Neurosurgery & Psychiatry 91, no. 9 (July 1, 2020): 960–67. http://dx.doi.org/10.1136/jnnp-2020-323487.
Full textSalami, Alireza, Rolf Adolfsson, Micael Andersson, Kaj Blennow, Anders Lundquist, Annelie Nordin Adolfsson, Michael Schöll, Henrik Zetterberg, and Lars Nyberg. "Association of APOE ɛ4 and Plasma p-tau181 with Preclinical Alzheimer’s Disease and Longitudinal Change in Hippocampus Function." Journal of Alzheimer's Disease 85, no. 3 (February 1, 2022): 1309–20. http://dx.doi.org/10.3233/jad-210673.
Full textTrelle, Alexandra N., Valerie A. Carr, Edward N. Wilson, Michelle S. Swarovski, Madison P. Hunt, Tyler N. Toueg, Tammy T. Tran, et al. "Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease." Neurology 96, no. 10 (January 6, 2021): e1470-e1481. http://dx.doi.org/10.1212/wnl.0000000000011477.
Full textLi, Ge, Cynthia L. Mayer, Daniel Morelli, Steven P. Millard, Wendy H. Raskind, Eric C. Petrie, Monique Cherrier, Anne M. Fagan, Murray A. Raskind, and Elaine R. Peskind. "Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults." Neurology 89, no. 12 (August 18, 2017): 1251–55. http://dx.doi.org/10.1212/wnl.0000000000004392.
Full textMaarouf, Chera L., Thomas G. Beach, Charles H. Adler, Michael Malek-Ahmadi, Tyler A. Kokjohn, Brittany N. Dugger, Douglas G. Walker, et al. "Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology." Biomarker Insights 8 (January 2013): BMI.S11422. http://dx.doi.org/10.4137/bmi.s11422.
Full textArcaro, Marina, Chiara Fenoglio, Maria Serpente, Andrea Arighi, Giorgio G. Fumagalli, Luca Sacchi, Stefano Floro, et al. "A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease." Biomedicines 10, no. 10 (October 21, 2022): 2667. http://dx.doi.org/10.3390/biomedicines10102667.
Full textEwers, Michael, Nicolai Franzmeier, Marc Suárez-Calvet, Estrella Morenas-Rodriguez, Miguel Angel Araque Caballero, Gernot Kleinberger, Laura Piccio, et al. "Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease." Science Translational Medicine 11, no. 507 (August 28, 2019): eaav6221. http://dx.doi.org/10.1126/scitranslmed.aav6221.
Full textSantangelo, Roberto, Alessandro Dell'Edera, Arianna Sala, Giordano Cecchetti, Federico Masserini, Francesca Caso, Patrizia Pinto, et al. "The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy “In Vivo” in the Differential Diagnosis of Alzheimer’s Dementia." Current Alzheimer Research 16, no. 7 (September 4, 2019): 587–95. http://dx.doi.org/10.2174/1567205016666190725150836.
Full textMeyer, Pierre‐François, Nicholas J. Ashton, Thomas K. Karikari, Cherie Strikwerda‐Brown, Theresa Köbe, Julie Gonneaud, Alexa Pichet Binette, et al. "Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults." Annals of Neurology 91, no. 4 (February 18, 2022): 548–60. http://dx.doi.org/10.1002/ana.26308.
Full textSmirnov, Denis S., Nicholas J. Ashton, Kaj Blennow, Henrik Zetterberg, Joel Simrén, Juan Lantero-Rodriguez, Thomas K. Karikari, et al. "Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change." Acta Neuropathologica 143, no. 4 (February 23, 2022): 487–503. http://dx.doi.org/10.1007/s00401-022-02408-5.
Full textPark, Jung Eun, Kyu Yeong Choi, Byeong C. Kim, Seong-Min Choi, Min-Kyung Song, Jang Jae Lee, Jahae Kim, et al. "Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment." Dementia and Geriatric Cognitive Disorders Extra 9, no. 1 (March 12, 2019): 100–113. http://dx.doi.org/10.1159/000496920.
Full textÁlvarez-Sánchez, Lourdes, Carmen Peña-Bautista, Laura Ferré-González, Angel Balaguer, Miguel Baquero, Bonaventura Casanova-Estruch, and Consuelo Cháfer-Pericás. "Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia." International Journal of Molecular Sciences 24, no. 2 (January 8, 2023): 1226. http://dx.doi.org/10.3390/ijms24021226.
Full textAshton, Nicholas J., Tharick A. Pascoal, Thomas K. Karikari, Andréa L. Benedet, Juan Lantero-Rodriguez, Gunnar Brinkmalm, Anniina Snellman, et al. "Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology." Acta Neuropathologica 141, no. 5 (February 14, 2021): 709–24. http://dx.doi.org/10.1007/s00401-021-02275-6.
Full textRizzi, Liara, Marcelle Maria Portal, Carlos Eduardo Alves Batista, Luciane Missiaggia, and Matheus Roriz-Cruz. "CSF Aβ1–42, but not p-Tau181, differentiates aMCI from SCI." Brain Research 1678 (January 2018): 27–31. http://dx.doi.org/10.1016/j.brainres.2017.10.008.
Full textSingh, Kailash, Bernard MY Cheung, and Aimin Xu. "Ultrasensitive detection of blood biomarkers of Alzheimer's and Parkinson's diseases: a systematic review." Biomarkers in Medicine 15, no. 17 (December 2021): 1693–708. http://dx.doi.org/10.2217/bmm-2021-0219.
Full textTzartos, John S., Fotini Boufidou, Christos Stergiou, Jens Kuhle, Eline Willemse, Lina Palaiodimou, Ioanna Tsantzali, et al. "Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders." Biomolecules 12, no. 8 (August 10, 2022): 1099. http://dx.doi.org/10.3390/biom12081099.
Full textKoychev, Ivan, Katrin Jansen, Alina Dette, Liu Shi, and Heinz Holling. "Blood-Based ATN Biomarkers of Alzheimer’s Disease: A Meta-Analysis." Journal of Alzheimer's Disease 79, no. 1 (January 5, 2021): 177–95. http://dx.doi.org/10.3233/jad-200900.
Full textJiang, Lijun, Xulong Ding, Wenxiao Wang, Xiaobin Yang, Tao Li, and Peng Lei. "Head-to-Head Comparison of Different Blood Collecting Tubes for Quantification of Alzheimer’s Disease Biomarkers in Plasma." Biomolecules 12, no. 9 (August 28, 2022): 1194. http://dx.doi.org/10.3390/biom12091194.
Full textBlanco-Cantó, Maria Empar, J. A. Monge-Argilés, C. Pérez-Cejuela, C. Badía, L. Gabaldón, C. Muñoz-Ruíz, J. Sánchez-Payá, R. Gasparini-Berenguer, and C. Leiva-Santana. "Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer’s Disease Biomarkers." American Journal of Alzheimer's Disease & Other Dementiasr 32, no. 2 (February 13, 2017): 101–7. http://dx.doi.org/10.1177/1533317516688298.
Full textBorroni, Barbara, Alberto Benussi, Silvana Archetti, Daniela Galimberti, Lucilla Parnetti, Benedetta Nacmias, Sandro Sorbi, Elio Scarpini, and Alessandro Padovani. "Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia." Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 16, no. 1-2 (October 29, 2014): 86–91. http://dx.doi.org/10.3109/21678421.2014.971812.
Full textHu, W. T., K. Watts, M. Grossman, J. Glass, J. J. Lah, C. Hales, M. Shelnutt, V. Van Deerlin, J. Q. Trojanowski, and A. I. Levey. "Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP." Neurology 81, no. 22 (October 30, 2013): 1945–52. http://dx.doi.org/10.1212/01.wnl.0000436625.63650.27.
Full textGramotnev, Dmitri K., Galina Gramotnev, Alexandra Gramotnev, and Mathew J. Summers. "Path analysis of biomarkers for cognitive decline in early Parkinson’s disease." PLOS ONE 17, no. 5 (May 13, 2022): e0268379. http://dx.doi.org/10.1371/journal.pone.0268379.
Full textBousiges, Olivier, Stephanie Bombois, Susanna Schraen, David Wallon, Muriel Muraine Quillard, Audrey Gabelle, Sylvain Lehmann, et al. "Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage." Journal of Neurology, Neurosurgery & Psychiatry 89, no. 5 (January 10, 2018): 467–75. http://dx.doi.org/10.1136/jnnp-2017-316385.
Full textBucci, Marco, Konstantinos Chiotis, and Agneta Nordberg. "Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline." Molecular Psychiatry 26, no. 10 (October 2021): 5888–98. http://dx.doi.org/10.1038/s41380-021-01263-2.
Full textTsiknia, Amaryllis A., Steven D. Edland, Erin E. Sundermann, Emilie T. Reas, James B. Brewer, Douglas Galasko, and Sarah J. Banks. "Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression." Molecular Psychiatry, June 29, 2022. http://dx.doi.org/10.1038/s41380-022-01675-8.
Full textClark, Christopher, Piotr Lewczuk, Johannes Kornhuber, Jonas Richiardi, Bénédicte Maréchal, Thomas K. Karikari, Kaj Blennow, Henrik Zetterberg, and Julius Popp. "Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression." Alzheimer's Research & Therapy 13, no. 1 (March 25, 2021). http://dx.doi.org/10.1186/s13195-021-00805-8.
Full textShen, Xue-Ning, Yu-Yuan Huang, Shi-Dong Chen, Yu Guo, Lan Tan, Qiang Dong, Jin-Tai Yu, et al. "Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status." Translational Psychiatry 11, no. 1 (November 13, 2021). http://dx.doi.org/10.1038/s41398-021-01709-9.
Full textZettergren, Anna, Jodie Lord, Nicholas J. Ashton, Andrea L. Benedet, Thomas K. Karikari, Juan Lantero Rodriguez, Anniina Snellman, et al. "Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative." Alzheimer's Research & Therapy 13, no. 1 (January 8, 2021). http://dx.doi.org/10.1186/s13195-020-00754-8.
Full textZettergren, Anna, Jodie Lord, Nicholas J. Ashton, Andrea L. Benedet, Thomas K. Karikari, Juan Lantero Rodriguez, Anniina Snellman, et al. "Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative." Alzheimer's Research & Therapy 13, no. 1 (January 8, 2021). http://dx.doi.org/10.1186/s13195-020-00754-8.
Full textLleó, Alberto, Henrik Zetterberg, Jordi Pegueroles, Thomas K. Karikari, María Carmona-Iragui, Nicholas J. Ashton, Victor Montal, et al. "Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome." Nature Communications 12, no. 1 (July 14, 2021). http://dx.doi.org/10.1038/s41467-021-24319-x.
Full textWang, Yan-Li, Jinglong Chen, Zhong-Li Du, Haoyi Weng, Yuan Zhang, Runzhi Li, Ziyan Jia, et al. "Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study." Frontiers in Neurology 12 (September 7, 2021). http://dx.doi.org/10.3389/fneur.2021.695696.
Full textJanelidze, Shorena, Erik Stomrud, Ruben Smith, Sebastian Palmqvist, Niklas Mattsson, David C. Airey, Nicholas K. Proctor, et al. "Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease." Nature Communications 11, no. 1 (April 3, 2020). http://dx.doi.org/10.1038/s41467-020-15436-0.
Full textTherriault, Joseph, Andrea L. Benedet, Tharick A. Pascoal, Firoza Z. Lussier, Cecile Tissot, Thomas K. Karikari, Nicholas J. Ashton, et al. "Association of plasma P-tau181 with memory decline in non-demented adults." Brain Communications 3, no. 3 (June 14, 2021). http://dx.doi.org/10.1093/braincomms/fcab136.
Full textMcGrath, Emer R., Alexa S. Beiser, Adrienne O’Donnell, Qiong Yang, Saptaparni Ghosh, Mitzi M. Gonzales, Jayandra J. Himali, et al. "Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults." Journal of Alzheimer's Disease, April 25, 2022, 1–10. http://dx.doi.org/10.3233/jad-215639.
Full textMcGrath, Emer R., Alexa S. Beiser, Adrienne O’Donnell, Qiong Yang, Saptaparni Ghosh, Mitzi M. Gonzales, Jayandra J. Himali, et al. "Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults." Journal of Alzheimer's Disease, April 25, 2022, 1–10. http://dx.doi.org/10.3233/jad-215639.
Full textMoscoso, Alexis, Michel J. Grothe, Nicholas J. Ashton, Thomas K. Karikari, Juan Lantero Rodriguez, Anniina Snellman, Marc Suárez-Calvet, Henrik Zetterberg, Kaj Blennow, and Michael Schöll. "Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum." Brain, November 30, 2020. http://dx.doi.org/10.1093/brain/awaa399.
Full textAsken, Breton M., Jeremy A. Tanner, Lawren VandeVrede, William G. Mantyh, Kaitlin B. Casaletto, Adam M. Staffaroni, Renaud La Joie, et al. "Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology." Neurology, May 16, 2022, 10.1212/WNL.0000000000200678. http://dx.doi.org/10.1212/wnl.0000000000200678.
Full textChen, Shi-Dong, Yu-Yuan Huang, Xue-Ning Shen, Yu Guo, Lan Tan, Qiang Dong, and Jin-Tai Yu. "Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease." Translational Psychiatry 11, no. 1 (June 2021). http://dx.doi.org/10.1038/s41398-021-01476-7.
Full textGrothe, Michel J., Alexis Moscoso, Nicholas J. Ashton, Thomas K. Karikari, Juan Lantero-Rodriguez, Anniina Snellman, Henrik Zetterberg, Kaj Blennow, and Michael Schöll. "Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy." Neurology, July 15, 2021, 10.1212/WNL.0000000000012513. http://dx.doi.org/10.1212/wnl.0000000000012513.
Full textBaiardi, Simone, Corinne Quadalti, Angela Mammana, Sofia Dellavalle, Corrado Zenesini, Luisa Sambati, Roberta Pantieri, et al. "Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias." Alzheimer's Research & Therapy 14, no. 1 (October 12, 2022). http://dx.doi.org/10.1186/s13195-022-01093-6.
Full textPilotto, Andrea, Marta Parigi, Giulio Bonzi, Beatrice Battaglio, Elisabetta Ferrari, Lorenza Mensi, Alberto Benussi, et al. "Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer’s Disease." Journal of Alzheimer's Disease, April 5, 2022, 1–7. http://dx.doi.org/10.3233/jad-215646.
Full textSarto, Jordi, Raquel Ruiz-García, Núria Guillén, Óscar Ramos-Campoy, Neus Falgàs, Diana Esteller, José Contador, et al. "Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort." Neurology, November 30, 2022, 10.1212/WNL.0000000000201597. http://dx.doi.org/10.1212/wnl.0000000000201597.
Full textMorrison, Madeline S., Hugo J. Aparicio, Kaj Blennow, Henrik Zetterberg, Nicholas J. Ashton, Thomas K. Karikari, Yorghos Tripodis, et al. "Antemortem plasma phosphorylated tau (181) predicts Alzheimer’s disease neuropathology and regional tau at autopsy." Brain, May 13, 2022. http://dx.doi.org/10.1093/brain/awac175.
Full textLeuzy, Antoine, Shorena Janelidze, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Dirk Jacobs, Claudia Cicognola, Erik Stomrud, Eugeen Vanmechelen, Jeffrey L. Dage, and Oskar Hansson. "Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays." Neurology, September 7, 2021, 10.1212/WNL.0000000000012727. http://dx.doi.org/10.1212/wnl.0000000000012727.
Full textBatzu, Lucia, Silvia Rota, Abdul Hye, Amanda Heslegrave, Dhaval Trivedi, Lucy L. Gibson, Chloe Farrell, et al. "Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease." npj Parkinson's Disease 8, no. 1 (November 12, 2022). http://dx.doi.org/10.1038/s41531-022-00384-x.
Full textWilson, Edward N., Christina B. Young, Javier Ramos Benitez, Michelle S. Swarovski, Igor Feinstein, Manu Vandijck, Yann Le Guen, et al. "Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease." Alzheimer's Research & Therapy 14, no. 1 (November 12, 2022). http://dx.doi.org/10.1186/s13195-022-01116-2.
Full textXiao, Zhenxu, Xue Wu, Wanqing Wu, Jingwei Yi, Xiaoniu Liang, Saineng Ding, Li Zheng, et al. "Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease." Alzheimer's Research & Therapy 13, no. 1 (July 5, 2021). http://dx.doi.org/10.1186/s13195-021-00864-x.
Full textBayoumy, Sherif, Inge M. W. Verberk, Ben den Dulk, Zulaiga Hussainali, Marissa Zwan, Wiesje M. van der Flier, Nicholas J. Ashton, et al. "Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231." Alzheimer's Research & Therapy 13, no. 1 (December 2021). http://dx.doi.org/10.1186/s13195-021-00939-9.
Full textChen, Yi-He, Rong-Rong Lin, Hui-Feng Huang, Yan-Yan Xue, and Qing-Qing Tao. "Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum." Frontiers in Aging Neuroscience 14 (June 30, 2022). http://dx.doi.org/10.3389/fnagi.2022.848180.
Full text